SAB--a promising new treatment to improve remission rates in AML in the elderly?

Br J Haematol. 2002 Aug;118(2):432-3. doi: 10.1046/j.1365-2141.2002.03620.x.

Abstract

This short report presents the results of a comparison of complete remission rates and reasons for failure, between two series of patients aged 60 years or over with acute myeloid leukaemia (AML), and discusses their interpretation.

MeSH terms

  • Acute Disease
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cytarabine / administration & dosage
  • Daunorubicin / administration & dosage
  • Disease-Free Survival
  • Humans
  • Leukemia, Myeloid / drug therapy*
  • Remission Induction
  • Thioguanine / administration & dosage

Substances

  • Cytarabine
  • Thioguanine
  • Daunorubicin

Supplementary concepts

  • DAT protocol 1